Upgraded Outlook and New Institutional Interest Might Change The Case For Investing In Boston Scientific (BSX)

• In recent weeks, Boston Scientific reported strong Q3 2025 results, highlighting robust growth in its cardiovascular product lines and raising its adjusted 2025 EPS outlook.
• This performance has helped draw in additional institutional investors and keep analysts positive on the company’s prospects despite earlier share price volatility.
• We’ll now explore how the upgraded earnings outlook and growing institutional interest could influence Boston Scientific’s broader investment narrative.

Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

Boston Scientific Investment Narrative Recap

To own Boston Scientific, you need to believe its cardiovascular and other high value devices can keep offsetting cost headwinds, competition and reimbursement pressure. The strong Q3 2025 earnings and raised 2025 EPS outlook support that thesis in the near term but do not remove the risk that tariffs and product discontinuations could weigh on margins if conditions change.

The most relevant update here is Boston Scientific’s Q3 2025 report, where cardiovascular strength helped lift adjusted full year EPS guidance. That improved earnings outlook sits against ongoing cost headwinds, including the expected US$100 million tariff impact in the second half of 2025, which remains a critical factor for near term profitability and investor confidence.

But before focusing only on the upgraded guidance, investors should be aware of how potential U.S. reimbursement cuts could...

Read the full narrative on Boston Scientific (it's free!)

Boston Scientific’s narrative projects $25.4 billion in revenue and $4.8 billion in earnings by 2028.

Uncover how Boston Scientific's forecasts yield a $126.48 fair value, a 32% upside to its current price.

Exploring Other Perspectives

Seven Simply Wall St Community fair value estimates for Boston Scientific span roughly US$68.64 to US$126.48, showing how far apart individual views can be. When you set those against the raised 2025 EPS outlook and ongoing tariff pressures, it underlines why many investors compare several contrasting perspectives before forming a view on the stock.

Explore 7 other fair value estimates on Boston Scientific - why the stock might be worth 29% less than the current price!

Build Your Own Boston Scientific Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Boston Scientific research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com